The MIT Startup Exchange is looking for 4-6 MIT-connected startups to present and exhibit at the 2019 MIT Paris Symposium, November 8, 2019. Each selected startup will have ~3 minutes to present a lightning talk on a science-based technology they are bringing to market, including one compelling use case.
CSAIL Alliances hosts a VC Breakfast twice each semester, connecting venture capitalists with the MIT startup community. This month’s guest is Commonwealth Alternatives. The fund invests in early-stage, revenue-generating companies, primarily from MIT, with a mission to address significant societal challenges through innovative products and services.
The Taiwan Chip-based Industrial Innovation Program (Taiwan CbI) is a collaborative effort by various Taiwanese government ministries, leveraging Taiwan’s semiconductor expertise by integrating chips with key innovations. Startups should be focused on IC design innovations and Chip-based innovative applications in the following industries: data & security, mobility, sustainability, manufacturing and medtech.
MIT Startup Exchange is working with IHS Markit and the MIT Energy Initiative to feature MIT Startups as speakers at the CERAWeek® Agora Innovation program, 9 - 12 March 2020, in Houston.
The 2024 MIT Health Science Technology Conference will highlight broad and transformative trends in biology and healthcare, including early-stage discovery, immune cell responses, diagnostics, clinical capabilities, process development, rapid and continuous manufacturing, robotics and automation, and sustainability, all enhanced by artificial intelligence and machine learning technologies. Leading MIT researchers and MIT-connected startups will showcase these advances and discuss their implications for improving human health.
Presentation opportunity in Japan and Korea.
AI Driven Bloodless Blood Tests Sean (Shunsuke) Matsuoka, Co-Founder & COO, GPx GPx: https://gpx.ai/
In an aging society, the number of heart failure patients is increasing, making the prevention of readmissions and reduction of medical costs critical issues. Remote monitoring using invasive implantable devices has proven effective in reducing heart failure readmissions, but its use remains limited.
To address this, GPx has developed an algorithm that non-invasively predicts signs of heart failure exacerbation. This algorithm was created using clinical trial data from monitoring 245 heart failure patients over 6 months to a year at eight facilities, including the Mayo Clinic in the U.S. The algorithm links digital biomarker data with vital blood tests (NT-proBNP and creatinine) to achieve high-precision prediction and early medical intervention.
Additionally, with a grant of 1.2 billion yen provided through AMED, we are collaborating with the National Cerebral and Cardiovascular Center (Dr. Chisato Izumi) to conduct a clinical trial involving 400 patients starting April 2025. The trial will be conducted at the National Cerebral and Cardiovascular Center, Kyoto University, Kobe University, and Kochi University.
Furthermore, at this year's MIT Japan Conference, we will unveil a groundbreaking point-of-care (POC) potassium testing device for the first time. At the conference, we aim to explore the feasibility of applying our technology to other conditions (such as kidney failure, pulmonary arterial hypertension, and cardio-oncology) and to assess the potential for providing algorithm-based services for heart failure patients within Japan.
P&G Ventures is looking for solutions to help men age with vitality and live their fullest lives.